Learn More
Adoptive immunotherapy involving bolus-dose recombinant interleukin-2 (rIL-2) has been reported to induce tumor regression in some patients with cancer, but has been associated with severe fluid retention and cardiopulmonary stress. In an effort to preserve the efficacy but reduce the toxicity of this treatment, we used escalating doses of rIL-2 as a(More)
1009 Background: SOR, a multikinase inhibitor targeting tumor growth and angiogenesis, is indicated for adv renal and hepatocellular cancer. The Trials to Investigate the Efficacy of SOR (TIES) program is four double-blind, randomized, placebo (PL)-controlled, phase IIb screening trials assessing SOR+CRx for HER2-negative locally adv or metastatic (met) BC.(More)
The outcomes for patients with non-Hodgkin’s lymphoma (NHL) treated with high-dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) infusion by practicing oncologists in community cancer centers in the United States were determined. Eighty-three patients with NHL, who had failed conventional chemotherapy, underwent mobilization of PBSC with(More)
6060 Background: The purpose of this study was to evaluate human resource costs and patient time associated with the delivery of chemotherapy and management of chemotherapy-induced neutropenia (CIN). METHODS 400 medical professionals were surveyed regarding human resource time associated with medical tasks, and 189 patients were surveyed regarding time(More)
8114 Background: Anemia-related fatigue can decrease the quality of life in cancer patients (pts) receiving chemotherapy (ctx). METHODS This study used a cross-sectional survey design. Eligible pts had a diagnosis of cancer, were receiving ctx, and received either an erythropoietic agent or a colony-stimulating factor the month prior to the survey. The(More)
Chemotherapy can serve as a stimulus for mobilizing hematopoietic progenitor cells to the peripheral blood for harvest via leukapheresis. Mobilized peripheral blood stem cells (PBSC) support rapid hematologic reconstitution after bone marrow aplasia induced by intensive myelosuppressive treatments. Our purpose was to develop effective mobilization regimens(More)
Engraftment kinetics after high-dose chemotherapy (HDC) were evaluated in patients receiving autologous peripheral blood stem cell (PBSC) infusions with a low CD34+ cell content. Forty-eight patients were infused with <2.5 × 106 CD34+ cells/kg; 36 because of poor harvests and 12 because they electively received only a fraction of their harvested cells. A(More)
The authors determined outcomes for patients with localized high-risk breast cancer undergoing sequential outpatient treatment with conventional-dose adjuvant therapy, chemotherapy, and growth factor mobilization of peripheral blood stem cells (PBSC) and high-dose chemotherapy (HDC) with PBSC support in community cancer centers. Ninety-six patients with(More)
We conducted a multicenter, phase II trial of continuous-infusion recombinant interleukin-2 (rIL-2) and lymphokine-activated killer (LAK) cells. Patients had advanced cancer, measurable disease, and a good performance level. Treatment included a 5-day continuous infusion of 18 x 10(6) IU/m2/d of rIL-2 followed by 1 day of rest, 4 days of leukapheresis to(More)
The purpose of this study was to determine the effectiveness of second mobilization strategies in patients who yielded < 2.5 x 10(6) CD34+ PBSC/kg after initial mobilization. Repeat mobilization attempts were made with chemotherapy and G-CSF (n = 61) or G-CSF alone (n = 58) in patients who failed initial mobilization with chemotherapy and G-CSF (n = 92) or(More)